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observation of possible symptoms of opioid overdose. Vague signs
such as extreme sleepiness, breathing problems, or even “pinpoint”
pupils may prompt a family member or close friend to whip out this
life-saving device and spring into action!
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Physicians employed in operating and emergency rooms have
utilized opioid antagonist for almost half a century for the treatment
of opioid overdose. The prototype antagonist remains naloxone
hydrochloride, which actually received FDA approval back in 1971.
Why after so many years on the market is this medication now
being formulated in the form of an easy to use “auto-injector” that
was designed for non-medical professionals to be able to utilize at a
moment’s notice? Could this wonder product, being hailed as the best
possible safety tool available for life threatening opioid emergencies
actual make heroes out of lay people? [1].
Will marketing and providing to the family and caregivers of
chronic pain patients prevent the epidemic of opioid medication
related deaths of people in our country? What else can be done by
physicians and the U.S. Food and Drug Administration (FDA)
to reduce the unbelievable statistic of a death every 36 minutes
from an opioid overdose in the United States? With upwards of
17,000 Americans dying yearly from prescription opioid overdose,
accidently or intentionally via suicide& deliberate misuse, and
constantly consuming more and more of these powerful painkillersthe million dollar question remaining to be answered is: will a new
drug formulation device in the hands of laypeople really make a dent
in this crisis that in recent years has actually surpassed car accidents
as the leading cause of accidental death? [2].
This new formulation Evzio contains naloxone in a new useful
device: an “auto-injector” that was recently approved for the
emergency treatment of suspected opioid overdose. The FDA and
physicians see Evzio as a new “tool” to combat opioid abuse/misuse
related deaths. It will work in a manner similar to the epinephrine pen
which is marketed for the acute treatment of anaphylaxis. (EVZIO
contains a speaker that provides voice instructions to guide the user
through each step of the injection).When activated, an automatically
inserted needle delivers 0.4 mg of naloxone hydrochloride injection
intramuscularly or subcutaneously and afterwards fully retracts the
needle into its housing [3].
Caregivers will be expected to utilize this medication after an

http://evzio.com/hcp/index.php

For Evzio to be effective, it will have to be prescribed and probably
paid for by either the patient or the prescription insurance company.
Will the prescriber be willing to address the risk of opioid overdose
to their patients on high-dose opioids or just those with known
substance abuse or those with a history of addiction or past stays in
detox programs? Are we really naïve enough to believe that only those
people that are prescribed these powerful medications are at risk?
The numbers of “users” who acquire these pain killers from friends,
relatives and illegal “dealers” is unknown but surely an enormous and
unacceptable number that clearly has overwhelmed the ability of law
enforcement to eliminate.
I am all for prescribers suggesting Evzio to all their chronic
pain patients on high-dose opioids. The need for an explanation
on the risk of respiratory depression and death is crucial even if the
prescriber does not suspect abuse of opioids. Unintentional overdose
is a common term used by physicians and medical examiners after
patients consumed dozens of medications, often at extremely high
doses-many not even prescribed or acquired legally. Sounds a lot
like suicide? Unfortunately these are reported as “accidental” and
continue to be counted the same as a car accident of falling off a
building. For these and many other and unclear reasons most autopsy
reports will not even suggest that a patient was attempting to take
their life-without a suicide note!
This brings us back to the question of will this medication actually
be used by a family member if they see someone on their couch
breathing shallow?
It is unbelievable how much positivity is being reported with
naloxone! Reports of it being without risk or side effects have suggested
that the medication can be used by Good Samaritans who happen
to be bystanders positioned around the country with open arms and
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equipped with the life-saving antidote and unwavering willingness to
assist doctors and reduce society concerns of opioid death. Caregivers
must be educated about what to expect AFTER giving naloxone...
sweating, goose-bumps, increased heart rate, agitation, withdrawal
symptoms, and the lack of efficacy for overdoses of other medications
that may be onboard including benzodiazepines, etc.
It is also very important to remain aware that most opioids will
last longer than naloxone-so good luck encouraging patients to head
on down to the emergency room for additional doses of naloxone,
and further care including management of withdrawal symptoms.
Any physician, paramedic or researcher with experience injecting
naloxone into an unconscious patient, unresponsive due to large doses
of opioids on board, is well aware of dramatic increases in both blood
pressure (BP) and heart rate (HR) upon its pharmacological response.
It is not surprising that rapid “withdrawal-like” symptomatology
after IM or IV opioid antagonist treatment, including an unpleasant
increase in severe anxiety, palpitations, and hypertensive changes
will make this “marketed” and “inferred” safe and easy treatment a
very difficult and even potentially dangerous situation for these nonmedical professional bystanders who are only trying to help revive
someone who may be unresponsive in their humble and untrained
opinion.
Safety and complications from treatment apparently are not being
advertised as an issue with this newly marketed naloxone- injector
according to evzio.com:
“No clinically significant safety findings”
“No serious adverse events”
“No volunteer discontinuation or withdrawal”
This is not really that surprising since “real- world- use” implies“
out of a hospital settings” with obvious reduced availability of
heart rate or blood pressure monitoring devices or even medical
professionals that could use them properly and death that occurred
despite utilization of the naloxone-injector could be easily determined
to be due to “late” administration of this anecdote.
With drug companies downplaying any cardiovascular
complications or even side effects being associated with naloxone,
it will be interesting to watch for sympathomimetic-catecholinergic
surge with a corresponding rapid pulse following naloxone
administration. Myocardial Infarction/Stroke complications can and
will occur-especially in patients with risk factors including smoking
history, obesity, sedentary lifestyle (from their chronic pain) or
hypertension, hyperlipidemia and tachycardia.
The development of a severe hypertensive response after the
administration of the opiate antagonist naloxone was evaluated
in one study that characterized the potentially dangerous role of
blocking or antagonizing opioids and the potential alteration in
the regulation of blood pressure in patients. One individual studied
showed significant mean arterial pressure changes with a rise from a
baseline of 107 mmHg to 147 mmHg 145 min after naloxone injection
and infusion. After stopping naloxone, his blood pressure rapidly
returned to baseline. Thus, endogenous opioids appear to regulate

blood pressure in some hypertensive patients and opiate antagonists
must be administered with caution to these individuals [4].
It is shocking that despite evidence of cardiovascular side effects
in studies, few warnings have been provided about untoward side
effects that could manifest as dramatic changes in vital signs following
administration by lay people.
This is not the first time that naloxone has been suggested as a
panacea. Since naloxone is needed as rapidly as possible in an operating
room situation-intravenously use to reverse opioid overdose is the
most preferred route. Over the years, countless researchers have
tinkered with oral formulations for both treatment and reduction of
associated opioid agonist complications. A slowed gastrointestinalrelated complication has plagued man since the first use of opioid
agonists, and continues to contribute to both the unpleasantness and
even immobility of chronic pain patients. It is not uncommon for
patients on large doses of chronic and powerful opioids to require
multiple daily doses of stimulant cathartics and stool-softeners in an
effort to have regular bowel functions. The ineffectiveness of laxatives
to target the underlying cause of opioid-induced inhibition of gastric
motility and the resulting chronic associated constipation have led to
the development of treatments that utilize opioid receptor antagonists
including naloxone and methylnaltrexone to target receptors in the
gut preferentially.
Methylnaltrexone marketed under the name Relistor provides
peripherally-acting-opioid antagonism that has the ability to reverse
constipation in patients using opioid-agonists without affecting
analgesia or even precipitating withdrawals. A permanently charged
tetravalent nitrogen atom in its design prevents the crossing of the
blood–brain barrier. This predominant antagonist effects counteracts
troubling opioid-induced side effects such as itching and constipation,
all while not minimizing opioid effects in the brain responsible for
analgesia.
RELISTOR is marketed as a prescription medication indicated for
the treatment of opioid-induced constipation (OIC) in patients with
advanced illness who are receiving palliative care, when response to
laxative therapy has not been sufficient. Use of RELISTOR beyond
four months has not been studied. The usual dose schedule for
RELISTOR is once every other day, as needed, but no more than once
in a 24-hour period [5].
It has been suggested that naloxone, when given orally, has
negligible bioavailability but may actually counteract opioid-induced
constipation by blocking the action of opioid medications locally in
the gut. Because of a sophisticated understanding of pharmacokinetic
properties, naloxone activity in the gastrointestinal tract presumably
occurs before almost complete metabolism by the liver to the
medications necessary reduction to negligible drug activity in the
Central Nervous System (CNS) where opioid (pain) receptors
are located. Central effects of the oral naloxone are minimized by
utilizing sparse doses that benefit colon transit time and minimize
complications that would impair analgesia.
Utilizing this research, a new modified-release combination
product containing the strong opioid oxycodone plus the opioid
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antagonist naloxone is being researched for the treatment of “severe
pain, which can be adequately managed only with opioid analgesics”.
It is believed that this combination has unique characteristics that
“naloxone is added to counteract opioid-induced constipation by
blocking the action of oxycodone at opioid receptors locally in the
gut”. If research proves claims of “superior GI [gastrointestinal]
tolerability compared to previous treatment in a clinical practice
study” to be accurate, it will be just a matter of time before more
and diverse opioids will be reformulated with a combined agonist/
antagonist formula [4].
The marketing of oxycodone/naloxone tablets, and other
fixed dose combination products including previously marketed
pentazocine-naloxone and morphine/ naltrexone utilized agonist/
antagonist has been attempted in an effort to prevent reactions
from crushing or injecting these combination products. Naloxone
was considered a wonderful deterrent to tampering with oral pain
medications in an effort to prevent a patient from crushing and
injecting an oral opioid with the hope of getting a “greater high or
euphoria rush”.
The providing of warnings by physicians and pharmacists were
thought to reduce the incidence of severe and potentially lethal misusereactions. Unfortunately, the morphine/naltrexone formulation was
withdrawn not due to any failure by the science of the formulation
including any insignificant amount of sequestered naltrexone
reaching systemic circulation, but because of reports of potentially
fatal reaction upon patient tampering and the subsequent release
of naltrexone blunting the euphoria of opioids and precipitating
dangerous opioid withdrawal sequelae in opioid-dependent patient.
Suboxone (buprenorphine and naloxone) has become a very popular
treatment for opiate addiction and while abuse is still possible, it
appears to have less euphoria and reduced analgesia effects compared
with full-opioid agonists.
Naltrexone basically has the same pharmacological effects as
naloxone, but it is longer acting and does possess potent pharmacologic
effects when used orally. Naltrexone is often utilized prophylactically
to maintain abstinence from opioids and administered by specially
trained medical supervision under anesthesia to provide rapid
detoxification in addicted patients wishing to bypass the unpleasant
withdrawal syndrome. Naltrexone for Opiate Dependence has not
proven to be a breakthrough in allowing patients to remain free of
opioids. Patients cannot be started on this preventative treatment
until they have already been opioid free for at least a week due to its
ability to precipitate an opioid withdrawal in opioid-tolerant patient.

exogenous opioid effects could result in the necessity to utilize
potentially life-threatening opioid doses to sufficiently overcome the
competitive receptor blockade due to its unique pharmacological
properties: it is injected into a muscle, and cannot be removed from
the body, it duration (lasts for one month). Since the medication
blocks the effects of opioid-containing medicines that might
otherwise be prescribed for a patient for pain, cough, or diarrhea, a
patient may be limited in their ability to receive any opioid agonist
benefits if needed in the case of an emergency or severe illness.
In addition, hepatotoxicity is a known consequence with oral
or injectable naltrexone use. If symptoms or lab values indicate any
potential liver damage or hepatitis including stomach area pain lasting
more than a few days, yellowing of the whites of eyes, dark urine or
even tiredness would necessitate a medical judgment to discontinue
treatment would seem prudent.
Stopping overdoses is obviously not enough to combat the
current enormous multifactorial problem of opioid misuse and
abuse. Recent government pressures have also been focused on
rescheduling hydrocodone-based products in an effort to reduce the
quantities available for illegal or even legally prescribed use to the
more restrictive Drug Enforcement Administration (DEA) schedule/
class “II”. Currently refills and telephoned prescriptions are available
for the less restrictive class III-V opioid-based medications, with the
proposed rescheduling to class-II, refills and telephoned prescriptions
will no longer be allowed under the law. This of course does not reduce
the amount of opioids prescribed, abused or diverted-it just makes
prescribers of class-II more cognizant of its restrictive nature and
requires more work for writer (physician), dispenser (pharmacist/
nurse), and patient (potential chronic pain patient or possible abuser
of medications).
Pharmacist and Physicians for the most part do not support these
rescheduling measures due to the proposed increase in record keeping
requirements and additional roadblocks to filling what has been
considered useful and first-line for the treatment of mild, moderate
and moderately severe pain. With a potential switch from its longtime position as a class III controlled substance to the class II location,
concerns about what forces-if any will prevent physicians from leapfrogging their patients to the more powerful morphine, methadone,
hydromorphone, oxymorphone, or even oxycodone products?

VIVITROL® (naltrexone for extended-release injectable
suspension) is a long-acting opioid antagonist that was approved
by the FDA in 2006. It has been used as a treatment for alcohol
dependence and to prevent relapse to opioid dependence after opioid
detoxification. The recommended dose is 380 mg intramuscularly
once a month.

Another potential solution includes pharmacy manufactures
and researchers designing and creating more abuse-deterrent opioid
formulations as another strategy suggested by the medical community
and government theorist. Risk Evaluation and Mitigation Strategies
(REMS) which include FDA Mandated med-guides together with
Prescription Drug Monitoring Programs (PDMP) have done very
little possibly due to little cohesiveness between prescribers and
pharmacists to address this problem and work toward the creation of
a successful strategy to combat abuse and misuse.

Due to its powerful antagonistic properties, its use does have
potential dangerous consequences with its use. The blocking of

Nature gave man opioid agonists and scientists have created
antagonists to combat them. Which will prove the most powerful in
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the end? These antagonists sure are providing an interesting subplot
to the battle against opioid agonists. Sometimes in medicine it is
hard to determine what characteristics describe the antagonist hero
(naloxone) and that of the protagonist villain (Opioids)? Is the hero
(naloxone) really going to protect humanity from a powerful enemy
(Opioids)? Is pain no longer the evil bad guy? Are the prescribers,
pharmacists and drug pushers the enemies now? Are patients really
just non-competitors in this scenario and unable to stay out of “harm’s
way” or utilize powerful pain management treatments safely due to
unmanageable side effects or life-threatening dangers? We will see!
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